NeoGenomics, Inc. (NEO)

NeoGenomics, Inc. is trading at $16.65, down 3.48% on the session. The 50 day average sits at $17.47 and the 200 day at $12.47, which puts the stock in a uptrend. RSI is at 39.6, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $15.72 with resistance near $16.92, so that band frames the current range. Average daily movement is roughly $0.95, or about 5.7% of the share price, which is what any stop placement has to allow for. The overall health score of 51 out of 100 combines a trend score of 77, momentum of 27 and a risk score of 42.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.